Expert Interview
Third View: Discussing Teva's Recent Phase 3 Data for TEV-‘749 (olanzapine) as a Once-Monthly Injectable for Adult Patients Diagnosed with Schizophrenia.
Ticker(s): TEVAInstitution: Private Practice
- Treats 200 patients with schizophrenia and 300 with bipolar disorder
- Conducting significant % of calls via Zoom and Doximity.
- Specialize in working with people suffering from substance abuse issues, in particular opiate/heroin abuse.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
